1 / 22

Marcus Tan , Murray F Brennan, Deborah Kuk ,

The I mportance of Histologic Subtype for Outcome Prediction in Primary Retroperitoneal Sarcoma : A Single-Institution Study of 675 Patients . Marcus Tan , Murray F Brennan, Deborah Kuk , Li- Xuan Qin, Narasimhan Agaram , Nicole Moraco , Aimée Crago , Samuel Singer

farren
Télécharger la présentation

Marcus Tan , Murray F Brennan, Deborah Kuk ,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Importance of Histologic Subtype for Outcome Prediction in Primary Retroperitoneal Sarcoma: A Single-Institution Study of 675 Patients Marcus Tan, Murray F Brennan, Deborah Kuk, Li-XuanQin, NarasimhanAgaram, Nicole Moraco, AiméeCrago, Samuel Singer Memorial Sloan-Kettering Cancer Center Sarcoma Disease Management Program

  2. Histology & RP sarcoma Retroperitoneal sarcomas (RPS) • Complete resection is the only chance for cure • Role of radiation therapy and chemotherapy remain controversial • AJCC staging system of limited utility • Increasing understanding of differences in histologic types and subtypes • Need for histology-based models to better predict patterns of failure for individual patients

  3. Histology & RP sarcoma Aim and Hypothesis • Aim: To determine the prognostic significance of histologic type/subtype in a large series of patients with primary retroperitoneal sarcoma • Hypothesis: Each histologic type/subtype of retroperitoneal sarcoma is associated with distinct patterns of local and distant recurrence

  4. Histology & RP sarcoma Methods • Retrospective review of prospectively-maintained sarcoma database from July 1982 to July 2010 • 675 patients with primary, non-metastatic RPS (excluding desmoid& GIST) • Median follow-up for survivors 4.3 years • Survival calculated from time of initial operation

  5. Histology & RP sarcoma Tumor Characteristics

  6. Histology & RP sarcoma Operative Details *Subsequently excluded from analyses

  7. Histology & RP sarcoma Disease-Specific Death (DSD) by histologic type/subtype (n=184) n=632* p<0.0001 (n=227) (n=119) (n=32) (n=21) *Resected patients only

  8. Histology & RP sarcoma Multivariate analysis of DSD

  9. Histology & RP sarcoma Local Recurrence (LR) by histologic type/subtype n=574* p<0.0001 (n=173) (n=197) (n=113) (n=29) (n=18) *R0/R1 resections only

  10. Histology & RP sarcoma Multivariate analysis of LR

  11. Histology & RP sarcoma Local Recurrence Nomogram Low grade LMS MPNST DD LPS WD LPS High grade LMS SFT Concordance index 0.69

  12. Histology & RP sarcoma Distant Recurrence (DR) by histologic type/subtype (n=184) n=632* p<0.0001 (n=227) (n=119) (n=32) (n=21) *Resected patients only

  13. Histology & RP sarcoma Multivariate Analysis of DR

  14. Histology & RP sarcoma Distant Recurrence Nomogram Low grade LMS Other MPNST SFT WD LPS DD LPS High grade LMS Concordance index 0.72

  15. Histology & RP sarcoma Natural History by Histologic Type/Subtype Disease-Specific Death (n=184) Well-diff & myxoid liposarcoma (n=227) Dedifferentiated, RC & pleomorphic liposarcoma (n=119) High grade leiomyosarcoma (n=32) Solitary fibrous tumor (n=21) MPNST Local Recurrence Distant Recurrence

  16. Histology & RP sarcoma Natural History by Histologic Type/Subtype Disease-Specific Death (n=184) Well-diff & myxoid liposarcoma (n=227) Dedifferentiated, RC & pleomorphic liposarcoma (n=119) High grade leiomyosarcoma (n=32) Solitary fibrous tumor (n=21) MPNST Local Recurrence Distant Recurrence

  17. Histology & RP sarcoma Natural History by Histologic Type/Subtype Disease-Specific Death (n=184) Well-diff & myxoid liposarcoma (n=227) Dedifferentiated, RC & pleomorphic liposarcoma (n=119) High grade leiomyosarcoma (n=32) Solitary fibrous tumor (n=21) MPNST Local Recurrence Distant Recurrence

  18. Histology & RP sarcoma Natural History by Histologic Type/Subtype Disease-Specific Death (n=184) Well-diff & myxoid liposarcoma (n=227) Dedifferentiated, RC & pleomorphic liposarcoma (n=119) High grade leiomyosarcoma (n=32) Solitary fibrous tumor (n=21) MPNST Local Recurrence Distant Recurrence

  19. Histology & RP sarcoma Natural History by Histologic Type/Subtype Disease-Specific Death (n=184) Well-diff & myxoid liposarcoma (n=227) Dedifferentiated, RC & pleomorphic liposarcoma (n=119) High grade leiomyosarcoma (n=32) Solitary fibrous tumor (n=21) MPNST Local Recurrence Distant Recurrence

  20. Histology & RP sarcoma Summary • Liposarcoma, leiomyosarcoma and SFT are associated with late recurrence and death from disease (as long as 15 years from initial diagnosis) • Dedifferentiated liposarcoma and high grade leiomyosarcoma have similar DSS, but distinct patterns of local and distant recurrence. • SFT is associated with low local recurrence (<10%) but high distant recurrence (40% at 5 years)

  21. Histology & RP sarcoma Conclusions • Histologic subtypes of RPS have distinct differences in the incidence and timing of local and distant recurrence, as well as disease specific death • Multivariate models and nomograms estimating risk of DSD, LR and DR • Inform patients and physicians of an individual’s risk • May prove useful for selection of patients for clinical trials of: • Neo-adjuvant radiation • Neo-adjuvant/adjuvant chemotherapy • Molecular targeted therapy

  22. Acknowledgements MSKCC Sarcoma Database • July 1982-present • n=10,150 patients • 10,000 patients reached on May 21st, 2013 Funding: • NIH SPORE in Soft Tissue Sarcoma P50 CA 140146-01 • NIH Soft Tissue Sarcoma program project grant P01 CA 047179 • The David and Monica GorinSarcoma Fund

More Related